Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

The Future of Generic Drugs and Strategies for Commercial Success 2016-2021: The Patent Cliff is a Key Driver of Growth - Research and Markets

Research and Markets
Posted on: 24 Oct 16

Research and Markets has announced the addition of the "The Future of Generic Drugs and Strategies for Commercial Success" report to their offering.

The Future of Generic Drugs and Strategies for Commercial Success discusses trends in the global generic drugs market, and the evolving business strategies being adopted and leveraged by generic drug companies around the world.

The generic drugs market has seen rapid expansion for more than 30 years, and consistently achieves higher annual growth rates than the overall pharmaceutical market. The increase in generic drug activity can be primarily attributed to the promise of significant revenues from blockbuster drugs nearing patent expiry.

In the US - the largest generic drugs market by revenue - the number of generic drug approvals hit a record high in 2015, due to a new program that aimed to speed up approvals. There has also recently been a surge in the number of industry-transforming mergers and acquisitions, with companies looking to consolidate their position in this highly lucrative market.

This latest industry survey provides insightful analyses from different expert panels, including R&D and commercial, and highlight trends observed in key geographical markets. The survey examined key commercial issues and recent developments in the generic drugs market, such as the reasons behind the surge in mergers and acquisitions, and the likely effects on market dynamics.

It covered important factors currently driving or restraining the market, prospects for key therapy areas expected to exhibit significant levels of genericization in the coming years, and the most promising emerging markets for generic companies in terms of revenue potential. Additionally, the survey examined common business strategies and regulations being leveraged by global generic drug companies for market expansion.

The report covers key small molecule drugs whose patents will expire in the coming years, providing an in-depth assessment of potential generic competition, expected launch dates and the overall impact on global branded revenues to 2021. The top global generic drug companies by revenue are also examined, including financial performance and recent activity within the market.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Generic Drugs Market: Drivers and Restraints

4 Generic Drug Pipeline for Top Small Molecule Drugs in the Market

5 Strategies to Promote Generic Drug Usage by Companies

6 Government Policies and Strategies to Promote Generic Drug Usage

7 Mergers and Acquisitions in the Global Generic Drugs Market

8 Top Global Generic Drug Companies

9 Conclusion

10 Appendix

Companies Mentioned

  • Aspen
  • Fresenius Kabi
  • Hospira
  • Lupin
  • Mylan
  • Sandoz
  • Sun Pharma
  • Teva

For more information about this report visit

View source version on

Business Wire

Last updated on: 24/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.